TransCon IL-2 beta/gamma(Ascendis Pharma)

- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million - Conference call today at 8:00 am ET COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH are cementing our position as a leading global biopharma,” said Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma. “Our strong focus on science and making a meaningful difference for patients will continue to be the fundamental driver for our success.” Select Highlights & Anticipated 2026 Milestones YORVIPATH (palopegteriparatide, developed as TransCon PTH) YORVIPATH revenue for the first quarter of 2026 totaled €197 million, which for the U.S. includes normal seasonality and the temporary impact of additional patients supported by free drug, as well as a one-time impact in Europe Direct related to expanded market access. In the U.S., more than 1,000 new patient enrollments in the first quarter of 2026. As of March 31, 2026, more than 6,300 unique patient enrollments by more than 2,700 prescribing healthcare providers since launch in the U.S. Outside the U.S., continued expansion of commercial launches with full reimbursement. Now available commercially or through named patient programs in 35 countries. Ongoing label expansion trials through PaTHway60 (adults) and PaTHway Adolescent. YUVIWEL (navepegritide, developed as TransCon CNP) Received U.S. Food & Drug Administration (FDA) accelerated approval, indicated to increase linear growth in children 2 years of age and older with achondroplasia with open epiphyses. The FDA granted orphan drug exclusivity for YUVIWEL, which will run through February 27, 2033. As of May 1, 2026, more than 60 unique patient enrollments by more than 35 prescribing healthcare providers since U.S. commercial availability in April 2026. Marketing Authorisation Application remains under review by the European Medicines Agency, with a decision anticipated in the fourth quarter of 2026. Label expansion trial in infants with achondroplasia, reACHin, is ongoing with enrollment completion anticipated in the third quarter of 2026. Phase 3 trial planned to investigate TransCon CNP monotherapy for the treatment of hypochondroplasia in the second half of the year. SKYTROFA (lonapegsomatropin, developed as TransCon hGH) SKYTROFA revenue for the first quarter of 2026 totaled €44 million. Announced Week 52 data from the Phase 2 New InsiGHTS Trial in Turner syndrome that demonstrated comparable efficacy and safety to daily somatropin. Ongoing Phase 3 HighLiGHts basket trial across a range of established growth disorders including idiopathic short stature (ISS), SHOX deficiency, Turner syndrome, and small for gestational age (SGA). TransCon CNP + TransCon hGH Combination Therapy (navepegritide plus lonapegsomatropin) Announced Phase 2 COACH Trial Week 52 topline results demonstrating mean annualized growth velocity that exceeded the 97th percentile of average stature children, improvements in body proportionality, and a safety pro with TransCon CNP and TransCon hGH monotherapies. Announced additional Week 52 results from COACH demonstrating meaningful benefits beyond linear growth, including improvements in spinal canal dimensions and lower limb alignment, along with unprecedented improvements in arm span compared to monotherapy. Interim Week 78 data from COACH expected in the second quarter of 2026 with Week 104 data expected around year end. Oncology Program (onvapegleukin alfa) In the ongoing Phase 1/2 IL-BELIEVE Trial, TransCon IL-2 β/γ in combination with paclitaxel demonstrated improved median overall survival (OS) up to 10 months from 6-7 months for historical controls, with a generally well-tolerated safety pro patients with late-stage platinum-resistant ovarian cancer, validating the science behind TransCon IL-2 β/γ. As further internal oncology development does not align with our strategic focus, we have decided to discontinue internal development of TransCon IL-2 β/γ in Oncology and will explore other ways to maximize the value of this asset. Key Financial Highlights Total revenue for the first quarter of 2026 was €247 million, compared to €101 million during the same period in 2025. The year-over-year increase in revenue was primarily attributable to an increase in product revenue from YORVIPATH. Operating profit for the first quarter of 2026 totaled €25 million, reflecting a margin of 10.1%. On a non-IFRS basis, operating profit was €55 million * , reflecting a margin of 22.4% * . Net profit for the first quarter of 2026 totaled €629 million, or €9.75 per diluted share, including the recognition of previously unrecognized deferred tax assets of €679 million. On a non-IFRS basis, net profit was €18 million * , or €0.27 per diluted share * . As of March 31, 2026, Ascendis Pharma had cash and cash equivalents totaling €573 million, which includes the impact of repurchases under the previously announced share repurchase program of €52 million and the net settlement of certain Restricted Stock Units for €8 million, compared to cash and cash equivalents totaling €616 million as of December 31, 2025. Subsequent to March 31, 2026: On April 20, 2026, the Company’s ordinary shares commenced trading on The Nasdaq Global Select Market, replacing the prior listing of American Depositary Shares (ADSs). On May 6, 2026, Ascendis redeemed all $575 million aggregate principal amount of its outstanding 2.25% convertible notes due 2028. Within the redemption period, all holders of the convertible notes surrendered their notes for conversion, whereupon the Company delivered 3,635,813 ordinary shares, together with cash in lieu of any fractional shares. The conversion resulted in the settlement of the current liabilities of convertible notes, comprising borrowings and derivative liabilities totaling €733 million as of March 31, 2026. The carrying amount as of the settlement date will be reclassified to equity in the second quarter of 2026. Entered into agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $187.5 million in cash, before transaction-related expenses. The PRV was awarded by the FDA upon approval of YUVIWEL in February 2026. The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2026. * See “Non-IFRS Financial Measures” below for definitions of these non-IFRS measures and a reconciliation to the most directly comparable IFRS measures. First Quarter 2026 Financial Results Total revenue for the first quarter of 2026 was €247 million, compared to €101 million during the same period in 2025. The year-over-year increase in revenue was primarily attributable to an increase in product revenue from YORVIPATH. Total Revenue (In EUR'000s) Three Months Ended March 31, 2026 2025 Revenue Commercial products 240,853 96,028 Services and clinical supply 5,110 3,524 Licenses 638 1,402 Total revenue 246,601 100,954 Revenue from Commercial Products (In EUR'000s) Three Months Ended March 31, 2026 2025 Revenue from commercial products YORVIPATH ® 196,896 44,688 SKYTROFA ® 43,957 51,340 Total revenue from commercial products 240,853 96,028 Research and development expenses for the first quarter of 2026 were €59 million, compared to €87 million during the same period in 2025. The decrease was driven primarily by the completion of certain clinical trials and development activities within our Endocrinology Rare Disease and Oncology pipeline and the first quarter of 2026 being positively impacted by a reversal of prior period write-downs of pre-launch inventories related to YUVIWEL. Selling, general, and administrative expenses for the first quarter of 2026 were €145 million, compared to €101 million during the same period in 2025. The increase was primarily due to the impact from commercial expansion, including global launch activities. Total operating expenses for the first quarter of 2026 were €204 million compared to €188 million during the same period in 2025. Operating profit for the first quarter of 2026 was €25 million, compared to an operating loss of €104 million during the same period in 2025. The increase was primarily driven by the increase in product revenue. Net finance expenses for the first quarter of 2026 were €63 million, compared to €16 million during the same period in 2025. The increase was primarily driven by non-cash fair-value remeasurement of derivative liabilities associated with our convertible notes. Income taxes for the first quarter of 2026 included the recognition of previously unrecognized deferred tax assets of €679 million. For the first quarter of 2026, Ascendis Pharma reported net profit of €629 million, or €10.20 per share basic and €9.75 per share (diluted), compared to a net loss of €95 million, or €1.58 per share (basic and diluted), for the same period in 2025. Net profit for the first quarter of 2026 included the recognition of previously unrecognized deferred tax assets of €679 million. Cash flows used in operating activities for the first quarter of 2026 were €8 million compared to €14 million used during the same period in 2025. The change primarily reflects the prior-year period benefiting from the $100 million upfront payment received under our exclusive license agreement with Novo Nordisk, which did not recur in the current period, while the current period reflects improved operating performance offset by working capital build. As of March 31, 2026, Ascendis Pharma had cash and cash equivalents totaling €573 million, compared to €616 million as of December 31, 2025. As of March 31, 2026, Ascendis Pharma had 62,376,846 ordinary shares outstanding, including 265,251 held by the Company. Beginning with the first quarter of 2026, Ascendis Pharma is introducing supplemental non-IFRS financial measures that management believes will help investors evaluate the Company’s underlying operating performance from period to period and enhance comparability against peer companies. The non-IFRS measures presented are not a substitute for, and should be considered together with, the comparable IFRS measures. See the table below on page 14 for specific reconciling items. For the first quarter of 2026, non-IFRS operating profit was €55 million, compared to a non-IFRS operating loss of €79 million for the same period in 2025. For the first quarter of 2026, non-IFRS net profit was €18 million, or €0.27 earnings per diluted share, compared to a non-IFRS net loss of €73 million, or €1.22 loss per diluted share, for the same period in 2025. Conference Call and Webcast Information Ascendis Pharma will host a conference call and webcast today at 8:00 am Eastern Time (ET) to discuss its first quarter 2026 financial results. Those who would like to participate may access the live webcast here , or register in advance for the teleconference here . The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at . A replay of the webcast will be available in this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days. About Ascendis Pharma A/S Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ evolution into a leading global biopharma, (ii) Ascendis' strong focus on science and making a meaningful difference for patients as the fundamental driver for success, (iii) anticipated timing of a regulatory decision from the European Medicines Agency, (iv) anticipated timing and plans of clinical trials and development activities, (v) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (vi) Ascendis’ use of TransCon to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA ® , YORVIPATH ® , and YUVIWEL ® are trademarks owned by the Ascendis Pharma group. © May 2026 Ascendis Pharma A/S. Investor Contacts: Media Contact: Chad Fugere Melinda Baker Ascendis Pharma Ascendis Pharma +1 (650) 519-7494 +1 (650) 709-8875 FINANCIAL TABLES FOLLOW Ascendis Pharma A/S Unaudited Condensed Consolidated Statements of Profit or (Loss) and Comprehensive Income / (Loss) (In EUR'000s, except per share data) Three Months Ended March 31, 2026 2025 Consolidated Statement of Profit or (Loss) Revenue 246,601 100,954 Cost of sales (17,515 ) (17,517 ) Gross profit 229,086 83,437 Research and development expenses (59,044 ) (86,603 ) Selling, general, and administrative expenses (145,230 ) (101,046 ) Operating profit/(loss) 24,812 (104,212 ) Share of profit/(loss) of associates (10,251 ) 26,579 Finance income 4,517 28,854 Finance expenses (67,255 ) (44,786 ) Profit/(loss) before tax (48,177 ) (93,565 ) Income taxes (expenses) 677,516 (1,061 ) Net profit/(loss) for the period 629,339 (94,626 ) Attributable to owners of the Company 629,339 (94,626 ) Basic earnings/(loss) per share 10.20 (1.58 ) Diluted earnings/(loss) per share 9.75 (1.58 ) Consolidated Statement of Comprehensive Income or (Loss) Net profit/(loss) for the period 629,339 (94,626 ) Other comprehensive income/(loss) Items that may be reclassified subsequently to profit or (loss): Exchange differences on translating foreign operations 3,058 (75 ) Other comprehensive income/(loss) for the period, net of tax 3,058 (75 ) Total comprehensive income/(loss) for the period, net of tax 632,397 (94,701 ) Attributable to owners of the Company 632,397 (94,701 ) Ascendis Pharma A/S Unaudited Condensed Consolidated Statements of Financial Position (In EUR'000s) March 31, 2026 December 31, 2025 Assets Non-current assets Intangible assets 3,689 3,710 Property, plant and equipment 135,918 146,479 Investments in associates 23,560 32,526 Other receivables 27,367 10,870 Deferred tax assets 690,405 — 880,939 193,585 Current assets Inventories 314,342 301,533 Trade receivables 178,676 141,333 Income tax receivables 1,258 1,781 Other receivables 16,673 14,582 Prepayments 38,571 33,715 Cash and cash equivalents 572,820 616,041 1,122,340 1,108,985 Total assets 2,003,279 1,302,570 Equity and liabilities Equity Share capital 8,380 8,322 Distributable equity 479,593 (171,143 ) Total equity 487,973 (162,821 ) Non-current liabilities Borrowings 386,106 385,254 Contract liabilities 2,437 1,123 Deferred tax liabilities — 9,623 388,543 396,000 Current liabilities Convertible notes, due April 2028 Borrowings 448,176 429,391 Derivative liabilities 290,482 256,231 738,658 685,622 Other current liabilities Borrowings 62,382 57,141 Contract liabilities 5,364 4,944 Trade payables and accrued expenses 78,588 90,657 Other liabilities 57,316 58,204 Income tax payables 7,805 6,427 Provisions 176,650 166,396 388,105 383,769 1,126,763 1,069,391 Total liabilities 1,515,306 1,465,391 Total equity and liabilities 2,003,279 1,302,570 Ascendis Pharma A/S Unaudited Condensed Consolidated Statements of Cash Flow (In EUR'000s) Three Months Ended March 31, 2026 2025 Operating activities Net profit/(loss) for the period 629,339 (94,626 ) Reversal of finance income (4,517 ) (28,854 ) Reversal of finance expenses 67,255 44,786 Reversal of income taxes (677,516 ) 1,061 Adjustments for non-cash items: Non-cash consideration relating to revenue (638 ) (1,402 ) Share of (profit)/loss of associates 10,251 (26,579 ) Share-based payment 30,356 25,558 Depreciation and amortization 4,220 4,545 Impairment of property, plant and equipment — 7,508 Changes in working capital: Inventories (12,813 ) 2,538 Receivables (36,377 ) 98,032 Prepayments (4,852 ) (5,521 ) Contract liabilities 1,735 (4,054 ) Trade payables, accrued expenses and other liabilities (21,051 ) (40,767 ) Provisions 6,534 260 Cash flows generated from/(used in) operations (8,074 ) (17,515 ) Finance income received 4,518 4,208 Finance expenses paid (5,328 ) (954 ) Income taxes received/(paid) 1,163 (52 ) Cash flows from/(used in) operating activities (7,721 ) (14,313 ) Investing activities Payments received under finance leases 959 — Acquisition of intangible assets and property, plant and equipment (7,712 ) (703 ) Cash flows from/(used in) investing activities (6,753 ) (703 ) Financing activities Repayment of borrowings (8,580 ) (3,066 ) Proceeds from exercise of warrants 31,625 13,834 Acquisition of treasury shares (51,857 ) (17,396 ) Payment of withholding taxes under stock incentive programs (8,021 ) (11,396 ) Cash flows from/(used in) financing activities (36,833 ) (18,024 ) Increase/(decrease) in cash and cash equivalents (51,307 ) (33,040 ) Cash and cash equivalents at January 1 616,041 559,543 Effect of exchange rate changes on balances held in foreign currencies 8,086 (8,580 ) Cash and cash equivalents at March 31 572,820 517,923 Non-IFRS Financial Measures In addition to the financial information prepared in accordance with IFRS Accounting Standards (“IFRS”) as issued by the International Accounting Standards Board and as adopted by the European Union, this press release contains certain non-IFRS financial measures, including Non-IFRS Operating Profit/(Loss), Non-IFRS Net Profit/(Loss), Non-IFRS operating profit/(loss) margin, and Non-IFRS diluted earnings per share (“Non-IFRS Diluted EPS”). These non-IFRS measures are provided as supplemental information and should be considered in addition to, and not as a substitute for or superior to, the comparable measures prepared in accordance with IFRS. Management believes these non-IFRS measures support management's, analysts' and investors' overall understanding of the Company’s underlying financial performance and trends and facilitate comparisons among current and past periods. Since non-IFRS measures do not have standardized definitions and meanings, they may differ from the non-IFRS measures used by other companies, which reduces their usefulness as comparative financial measures. Because of these limitations, you should consider these adjusted financial measures alongside other IFRS financial measures. Because these non-IFRS measures are not prepared in accordance with IFRS, they should not be viewed as superior to IFRS reported measures, nor should they be used on their own or as replacements for the IFRS financial information included in this press release. Additionally, our non-IFRS measures may differ from similarly labeled measures used by other companies due to variations in calculation methods or the size and nature of adjusted items. Investors should note that several of the items excluded from these non-IFRS measures have been recognized in prior periods and may continue to be recognized in future periods. The Company reports Non-IFRS Operating Profit/(Loss), Non-IFRS Net Profit /(Loss), Non-IFRS operating profit/(loss) margin and Non-IFRS Diluted EPS as non-IFRS measures, which exclude the following specified items: (i) Share-based compensation expense. Although share-based compensation is a recurring expense, the Company excludes it from non-IFRS measures because the amount and timing of recognition depend on the value of the underlying equity instruments, which can fluctuate based on factors unrelated to the Company’s operating performance during the period. (ii) Share of profit/(loss) of associates. The Company excludes its share of the profit or loss of equity-method investees because these amounts are not within the control of the Company and do not reflect the Company’s core operating performance. (iii) Fair-value remeasurement of derivative liabilities related to the Company’s convertible notes. The Company excludes the fair-value remeasurement of derivative liabilities associated with its convertible notes because these amounts depend on movements in the Company’s share price and other market inputs and are not indicative of the Company’s underlying operating performance. (iv) Recognition of previously unrecognized deferred tax assets. The Company excludes the one-time recognition of previously unrecognized deferred tax assets because this item reflects a reassessment of the recoverability of historical tax attributes rather than the Company’s current period operating performance. Income taxes related to the foregoing items are adjusted accordingly, considering the individual impact of each item, the relevant tax jurisdiction, applicable tax rates, and the deductibility of the item. For further details regarding valuation of derivative liabilities, and the recognition of previously unrecognized deferred tax assets, please refer to “Note 3 – Significant Accounting Judgements and Estimates,” contained in our Interim Report on Form 6-K, for the period ended March 31, 2026 and “Note 3 – Significant Accounting Judgements and Estimates,” contained in our Annual Report on Form 20-F, for the year ended December 31, 2025. The following table provides a reconciliation of the most directly comparable IFRS measures to Non-IFRS Operating Profit/(Loss), Non-IFRS Net Profit/(Loss) and Non-IFRS Diluted EPS. Ascendis Pharma A/S Reconciliation of IFRS to Non-IFRS Financial Information (unaudited, in EUR'000s, except shares and per share data) Three Months Ended March 31, 2026 2025 IFRS operating profit/(loss) 24,812 (104,212 ) Share-based compensation costs 30,356 25,558 Total non-IFRS adjustments to operating profit/(loss) 30,356 25,558 Non-IFRS operating profit/(loss) 55,168 (78,654 ) IFRS operating profit/(loss) margin (%) 1 10.1 % (103.2 %) Non-IFRS operating profit/(loss) margin (%) 1 22.4 % (77.9 %) IFRS Net profit/(loss) 629,339 (94,626 ) Share-based compensation costs 30,356 25,558 Share of profit/(loss) of associates 10,251 (26,579 ) Remeasurement gain/(loss) of derivative liabilities 34,251 23,911 Recognition of previously unrecognized deferred tax assets (679,024 ) - Tax effects of adjustments (7,623 ) (1,640 ) Total non-IFRS adjustments to net profit/(loss) (611,789 ) 21,250 Non-IFRS net profit/(loss) 17,550 (73,376 ) Net profit/(loss) per diluted share: IFRS 9.75 (1.58 ) Diluted per share impact of total non-IFRS adjustments (9.48 ) 0.35 Non-IFRS 0.27 (1.22 ) Shares used in diluted per share calculation: IFRS 64,521,948 60,018,550 Non-IFRS 64,521,948 60,018,550 1 Defined as either IFRS or non-IFRS operating profit/(loss) divided by total revenue

Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 million Q4 2025 operating profit of €10 million and cash flow from operating activities of €73 million TransCon ® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026 Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “With a continued focus on making a meaningful difference for patients, we believe Ascendis is entering a steep growth phase as we transform into a leading global biopharma company,” said Jan Mikkelsen, President and CEO of Ascendis Pharma. “With strong execution and the power of our TransCon platform, we are positioned to generate approximately €500 million in operating cash flow in 2026 while aspiring to deliver at least €5 billion in global annual product revenue by 2030. At the same time, we are advancing a growing pipeline of highly differentiated programs to deliver durable, long-term growth.” Select 2025 Highlights & Anticipated 2026 Milestones TransCon PTH (palopegteriparatide, marketed as YORVIPATH) YORVIPATH revenue for the fourth quarter of 2025 totaled €187 million and €477 million for the full year 2025, as previously announced. More than 5,300 unique U.S. patient enrollments, with nearly 2,400 unique prescribing healthcare providers at year end. Outside the U.S., now available commercially or through named patient programs in more than 30 countries, with full commercial launches anticipated in 10 additional countries by year end 2026. Presented pooled analysis of 3-year data from PaTHway and PaTH Forward trials at the American Society of Nephrology (ASN) Kidney Week 2025, reinforcing that treatment with TransCon PTH led to rapid and sustained improvements in kidney function in adults with hypoparathyroidism. Ongoing label expansion trials through PaTHway60 (adults) and PaTHway Adolescent. Confirmed product pro once-weekly TransCon PTH, targeting patients who have been transitioned from conventional therapy to YORVIPATH and have achieved a stable daily dose. TransCon CNP (navepegritide, FDA NDA and EMA MAA filed) In the U.S., PDUFA action goal date of February 28, 2026 for pediatric achondroplasia. Submitted marketing authorization application (MAA) to the European Medicines Agency (EMA) in October 2025, with a regulatory decision on potential use in pediatric achondroplasia anticipated in the fourth quarter of 2026. Label expansion trial in infants with achondroplasia, reACHin, remains ongoing with enrollment completion anticipated later this year. TransCon CNP + TransCon hGH Combination Therapy ( navepegritide plus lonapegsomatropin ) Announced Week 52 topline results from Phase 2 COACH Trial, which demonstrated improvements in annualized growth velocity across both TransCon CNP treatment-naïve and TransCon CNP-treated children that exceeded the 97th percentile of average stature children, along with improvements in body proportionality and in arm span, and a safety pro with those observed for monotherapies of TransCon CNP and TransCon hGH on January 8, 2026. Held a successful end of Phase 2 meeting with the U.S. Food & Drug Administration (FDA) and Scientific Advice meeting in the EU regarding a Phase 3 trial of TransCon CNP and TransCon hGH in pediatric achondroplasia in the fourth quarter of 2025. Week 78 COACH data update anticipated in second quarter of 2026. Planned new trials to support TransCon CNP + TransCon hGH treatment in additional indications. TransCon hGH (lonapegsomatropin, marketed as SKYTROFA) SKYTROFA revenue for the fourth quarter of 2025 totaled €53 million and €206 million for the full year 2025, as previously announced. Received first label expansion in July 2025 with FDA approval for adult growth hormone deficiency (GHD). Initiated Phase 3 basket trial for additional indications: idiopathic short stature (ISS), SHOX deficiency, Turner syndrome, and small for gestational age (SGA). Oncology Program (onvapegleukin alfa) Expect to report median overall survival (OS) data for a cohort of 70 patients with late-line platinum-resistant ovarian cancer (PROC) from the IL-Believe Trial of TransCon IL-2 β/γ + weekly paclitaxel in the second quarter of this year. Strategic Collaborations & Investments Ongoing multi-product collaboration with Novo Nordisk for TransCon technology-based therapies in obesity and metabolic diseases, with the lead program, TransCon Semaglutide, on track to enter the clinic as anticipated. Eyconis lead program, TransCon aVEGF (EYC-0305), in development for wet AMD and other retinal diseases anticipated to enter the clinic in 2026. On January 26, 2026, VISEN Pharmaceuticals announced that China’s National Medical Products Administration approved its biologics license application for lonapegsomatropin (TransCon hGH) in China for the treatment of pediatric growth hormone deficiency (PGHD). In November 2025, Teijin Limited announced that YORVIPATH is commercially available for prescription in Japan. Financial Update For the fourth quarter of 2025, operating profit was €10 million and cash flow from operating activities was €73 million, primarily driven by continued growth of YORVIPATH revenue globally. Initiating previously announced $120 million share repurchase program in 2026. As of December 31, 2025, our cash balance was €616 million, an increase of €77 million compared to €539 million as of September 30, 2025. Fourth Quarter and Full-Year 2025 Financial Results Total revenue for the fourth quarter of 2025 was €248 million, compared to €174 million during the same period for 2024. The increase was primarily attributable to the continued growth of YORVIPATH global product revenue, partially offset by the recognition of a $100 million upfront payment in 2024 that did not recur in 2025. Total revenue for 2025 was €720 million compared to €364 million in 2024. The increase was primarily attributable to the continued growth of YORVIPATH partially offset by recognition of a $100 million upfront payment in 2024 that did not recur in 2025. Non-product revenue was €37 million in 2025, compared to €138 million in 2024. Total Revenue (In EUR'000s) Three Months Ended December 31, Twelve Months Ended December 31, 2025 2024 2025 2024 Revenue Commercial products 240,092 72,130 683,572 225,728 Services and clinical supply 4,780 5,933 18,008 15,570 Licenses 2,628 95,853 5,630 122,343 Milestones — — 12,922 — Total revenue 247,500 173,916 720,132 363,641 Commercial Products Revenue (In EUR'000s) Three Months Ended December 31, Twelve Months Ended December 31, 2025 2024 2025 2024 Revenue from commercial products YORVIPATH® 186,677 13,584 477,412 28,727 SKYTROFA® 53,415 58,546 206,160 197,001 Total revenue from commercial products 240,092 72,130 683,572 225,728 Research and development (R&D) expenses for the fourth quarter of 2025 were €78 million, compared to €79 million during the same period in 2024. R&D expenses for 2025 were €304 million compared to €307 million in 2024. The lower R&D expenses were driven by the completion of clinical trials and development activities within our Endocrinology Rare Disease pipeline partially offset by reversal (income) of prior period write-downs related to YORVIPATH pre-launch inventory. Selling, general, and administrative (SG&A) expenses for the fourth quarter of 2025 were €136 million, compared to €80 million during the same period in 2024. SG&A expenses for 2025 were €458 million compared to €291 million in 2024. Higher SG&A expenses were primarily due to the continued impact from global commercial expansion, including global launch activities for YORVIPATH. Total operating expenses for the fourth quarter of 2025 were €214 million compared to €160 million during the same period in 2024. Total operating expenses for 2025 were €761 million compared to €598 million in 2024. Net finance expenses were €38 million in the fourth quarter compared to €33 million in the same period in 2024. Net finance expenses for 2025 were €93 million compared to €74 million in 2024. The full year net finance expense increase was driven primarily by non-cash items. For the fourth quarter of 2025, Ascendis Pharma reported a net loss of €34 million, or €0.55 per share (basic and diluted) compared to a net loss of €38 million, or €0.64 per share (basic and diluted) for the same period in 2024. For the full year 2025, Ascendis Pharma reported a net loss of €228 million, or €3.76 per share (basic and diluted) compared to a net loss of €378 million, or €6.53 per share (basic and diluted) in 2024. As of December 31, 2025, Ascendis Pharma had cash and cash equivalents totaling €616 million compared to €560 million as of December 31, 2024. As of December 31, 2025, Ascendis Pharma had 61,977,408 ordinary shares outstanding, including 597,096 ordinary shares represented by ADSs held by the company. Conference Call and Webcast Information Ascendis Pharma will host a conference call and webcast today at 4:30 pm Eastern Time (ET) to discuss its fourth quarter and full year 2025 financial results. Those who would like to participate may access the live webcast here , or register in advance for the teleconference here . The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at . A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/S Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ expectation for durable, long-term growth, including its expectation to generate approximately €500 million in operating cash flow in 2026 and to deliver at least €5 billion in global annual product revenue by 2030; (ii) Ascendis’ expectations with respect to the commercial launches of TransCon PTH in additional countries; (iii) the PDUFA goal date for FDA review of TransCon CNP; (iv) the timing of EMA’s decision on potential use of TransCon CNP in pediatric achondroplasia; (v) the timing of enrollment completion of the label expansion trial in infants with achondroplasia, reACHin; (vi) the timing of Week 78 COACH data update; (vii) the planned new trials to support TransCon CNP + TransCon hGH treatment in additional indications; (viii) the timing of median OS data for the oncology program; (ix) the clinical entry of TransCon semaglutide; (x) the clinical entry of TransCon aVEGF program in 2026; (xi) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company; and (xii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; and the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA ® , and YORVIPATH ® are trademarks owned by the Ascendis Pharma group. © February 2026 Ascendis Pharma A/S. Investor Contacts: Chad Fugere Ascendis Pharma ir@ascendispharma.com Media Contact: Melinda Baker Ascendis Pharma media@ascendispharma.com Patti Bank ICR Healthcare patti.bank@icrhealthcare.com FINANCIAL TABLES FOLLOW Ascendis Pharma A/S Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (In EUR'000s, except share and per share data) Three Months Ended December 31, Twelve Months Ended December 31, 2025 2024 2025 2024 Consolidated Statement of Profit or (Loss) Revenue 247,500 173,916 720,132 363,641 Cost of sales (23,598 ) (14,023 ) (94,915 ) (44,258 ) Gross profit 223,902 159,893 625,217 319,383 Research and development expenses (78,151 ) (79,294 ) (303,621 ) (307,004 ) Selling, general, and administrative expenses (135,855 ) (80,216 ) (457,867 ) (291,142 ) Operating profit/(loss) 9,896 383 (136,271 ) (278,763 ) Share of profit/(loss) of associates 1,328 (4,575 ) 16,308 (20,060 ) Finance income 24,061 26,233 113,999 25,609 Finance expenses (61,990 ) (59,425 ) (206,687 ) (100,027 ) Profit/(loss) before tax (26,705 ) (37,384 ) (212,651 ) (373,241 ) Income taxes (expenses) (6,857 ) (1,085 ) (15,383 ) (4,843 ) Net profit/(loss) for the year (33,562 ) (38,469 ) (228,034 ) (378,084 ) Attributable to owners of the Company (33,562 ) (38,469 ) (228,034 ) (378,084 ) Basic earnings/(loss) per share € (0.55 ) € (0.64 ) € (3.76 ) € (6.53 ) Diluted earnings/(loss) per share € (0.55 ) € (0.64 ) € (3.76 ) € (6.53 ) Consolidated Statement of Comprehensive Income or (Loss) Net profit/(loss) for the year (33,562 ) (38,469 ) (228,034 ) (378,084 ) Other comprehensive income/(loss) Items that may be reclassified subsequently to profit or (loss): Exchange differences on translating foreign operations (490 ) 830 (3,538 ) 1,062 Other comprehensive income/(loss) for the year, net of tax (490 ) 830 (3,538 ) 1,062 Total comprehensive income/(loss) for the year, net of tax (34,052 ) (37,639 ) (231,572 ) (377,022 ) Attributable to owners of the Company (34,052 ) (37,639 ) (231,572 ) (377,022 ) Ascendis Pharma A/S Consolidated Statements of Financial Position (In EUR'000s) December 31, 2025 December 31, 2024 Assets Non-current assets Intangible assets 3,710 4,028 Property, plant and equipment 146,479 98,714 Investments in associates 32,526 13,575 Other receivables 10,870 2,317 193,585 118,634 Current assets Inventories 301,533 295,609 Trade receivables 141,333 166,280 Income tax receivables 1,781 1,775 Other receivables 14,582 9,385 Prepayments 33,715 28,269 Cash and cash equivalents 616,041 559,543 1,108,985 1,060,861 Total assets 1,302,570 1,179,495 Equity and liabilities Equity Share capital 8,322 8,149 Distributable equity (171,143 ) (113,855 ) Total equity (162,821 ) (105,706 ) Non-current liabilities Borrowings 385,254 365,080 Contract liabilities 1,123 5,000 Deferred tax liabilities 9,623 7,258 396,000 377,338 Current liabilities Convertible notes, matures in April 2028 Borrowings 429,391 458,207 Derivative liabilities 256,231 150,670 685,622 608,877 Other current liabilities Borrowings 57,141 33,329 Contract liabilities 4,944 936 Trade payables and accrued expenses 90,657 96,394 Other liabilities 58,204 67,956 Income tax payables 6,427 1,222 Provisions 166,396 99,149 383,769 298,986 1,069,391 907,863 Total liabilities 1,465,391 1,285,201 Total equity and liabilities 1,302,570 1,179,495